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Abstract: Background Malignant pheochromocytoma and paraganglioma (MPP) are characterized by
prognostic heterogeneity. Our objective was to look for prognostic parameters of overall survival in
MPP patients. Patients and Methods Retrospective multicentric study of MPP characterized by a neck-
thoraco-abdomino-pelvic CT or MRI at the time of malignancy diagnosis in European centers between
1998 and 2010. Results We included 169 patients from 18 European centers. Main characteristics of MPP
patients were: primary pheochromocytoma in 53% of patients, tumor or hormone-related symptoms in
57% or 58% of cases, positive plasma or urine hormones in 81% of patients, identification of a mutation
in SDHB in 42 % of cases. Metastatic sites included the bone (64%), lymph node (40%), lung (29%)
and liver (26%); mean time between initial and malignancy diagnosis was 43 months (0-614). Median
follow-up was 68 months and median survival 6.7 years. Using univariate analysis, better survival was
associated with head and neck paraganglioma, age <40 years, metanephrines <5-fold the upper limits
of the normal range and low proliferative index. In multivariate analysis, hypersecretion (Hazard Ratio
3.02[1.65-5.55]; p:0.0004) was identified as independent significant prognostic factors of worst overall
survival. Conclusions Our results do not confirm SDHB mutations as a major prognostic parameter in
MPP and suggest additional key molecular events involved in MPP tumor progression. Aside from SDHB
mutation, the biology of aggressive MPP remains to be understood.
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Background: Malignant pheochromocytoma and paraganglioma (MPP) are characterized by 
prognostic heterogeneity. Our objective was to look for prognostic parameters of overall 
survival in MPP patients. 
Patients and Methods: Retrospective multicentric study of MPP characterized by a neck-
thoraco-abdomino-pelvic CT or MRI at the time of malignancy diagnosis in European centers 
between 1998 and 2010. 
Results: We included 169 patients from 18 European centers. Main characteristics of MPP 
patients were: primary pheochromocytoma in 53% of patients, tumor or hormone-related 
symptoms in 57% or 58% of cases, positive plasma or urine hormones in 81% of patients, 
identification of a mutation in SDHB in 42 % of cases. Metastatic sites included the bone 
(64%), lymph node (40%), lung (29%) and liver (26%); mean time between initial and 
malignancy diagnosis was 43 months (0-614). Median follow-up was 68 months and median 
survival 6.7 years. Using univariate analysis, better survival was associated with head and 
neck paraganglioma, age <40 years, metanephrines <5-fold the upper limits of the normal 
range and low proliferative index. In multivariate analysis, hypersecretion (Hazard Ratio 
3.02[1.65-5.55]; p:0.0004) was identified as independent significant prognostic factors of 
worst overall survival. 
Conclusions: Our results do not confirm SDHB mutations as a major prognostic parameter in 
MPP and suggest additional key molecular events involved in MPP tumor progression. Aside 
from SDHB mutation, the biology of aggressive MPP remains to be understood. 
Retrospective study that identifies hormonal hypersecretion as independent significant prognostic 
factors of worst overall survival while SDHB mutations have no prognostic impact. 
Introduction 
Pheochromocytoma and paraganglioma are rare neuroendocrine chromaffin tumors located at 
adrenal or extra-adrenal sites and defined as malignant by the World Health Organization 
(WHO) by the occurrence of metastases in non-chromaffin organs (1). Malignant 
pheochromocytoma and paraganglioma (MPP) incidence is less than one case per million 
population per year (2). MPP are characterized by their heterogeneity including primary site 
location, genetic predisposition, hormonal secretion and metastatic organs (3). In addition, we 
recently demonstrated that half of MPP patients have stable disease at one year without any 
therapeutic intervention (4). Finally, heterogeneous survival has been described in the 
literature ranging from 40 to 77% at five year diagnosis (5–7) as well as  heterogeneous 
progression free survival ranged from 4 to 36 months in therapeutic trials (8–11).  
Pheochromocytoma and paraganglioma occurs as part of inherited syndrome in 40 % of 
case with up to 12 genes found related to this disease in the past two decades (12). Germline 
mutations in succinate deshydrogenase subunit B (SDHB) have been  associated with higher 
rate of metastatic disease as well as rare mutations in FH, MAX and SLC25A11 (13–17). Ten 
years ago, we previously reported that the presence or absence of SDHB mutation was 
associated with distinct median survival of 42 or 244 months in adults (5). The presence of 
the SDHB mutation was also associated with a low metastases-free survival in a pediatric 










































































































































































The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2018-01968 
 
 3
addition, other prognostic factors have been highlighted including age (7,19,21), extra-
adrenal location (7,22–24), primary tumor size (7,19,22,24) or synchronous metastatic 
disease (7,19–21).  
In this study, we retrospectively looked for prognostic factors of overall survival in a 
large series of patients with MPP followed up within the European Network for the Study of 
Adrenal Tumors (ENS@T).  
Patients and Methods 
Patients 
The medical files of MPP patients, followed up between January 1998 and December 2010 
were reviewed in 18 centers of ENS@T. Clinical data were entered in the ENS@T database 
by each center and then data were extracted and reviewed by one investigator (SH). An 
informed consent was obtained from all patients. Patients with the following criteria were 
included in the MAPP-Prono study (MetAstatic Pheochromocytoma and Paraganglioma 
PRONOstic study): 1. Confirmed diagnosis of MPP (including pheochromocytoma, 
abdominal, thoracic or head and neck paraganglioma) as defined by the presence of distant 
metastasis between 1998 and 2010; 2.  Neck-Thoracic-abdomen-pelvic CT (TAP CT) 
performed within 4 months of metastasis diagnosis 3. Entire follow-up in the center. 
Exclusion criteria were: 1. Benign pheochromocytoma and paraganglioma; 2. Patients with 
venous or loco-regional or proximal lymph node spread, only. 
The following parameters were recorded at the time of first TAP CT in the metastatic 
setting:  gender, age, genetic status of dedicated genes including SDHB mutation analysis 
according to available guidelines at the time of patient management, location and size of the 
primary tumor, metastatic sites (bone, lymph nodes, lung, and liver), presence of hormone- or 
tumor-related symptoms, chromogranin A and total metanephrine levels, the mitotic count 
and Ki67 and the interval between the initial diagnosis and that of metastasis. Hormonal 
secretion was defined as elevated chromogranin A and/or metanephrines (i.e. 2-fold the upper 
limits of the normal range). Causes of death, related or not to MPP and status at last follow-
up were recorded. The description and cut-off values of each parameter as well as the number 
of patients evaluable for each parameter are given in Table 1. 
Statistical analysis  
Quantitative values are reported as means +/- standard deviations (SD) or median [IQR] and 
categorical variables as percentages. Differences according to patients’ characteristics were 
assessed using the chi-2 test or non-parametric Mann Whitney U-tests. A p value < 0.05 was 
considered significant. The primary endpoint of the study was overall survival (OS) defined 
by time from diagnosis of MPP (first thorax-abdomen or head and neck CT in the metastatic 
setting) (time zero: T0) to death by any cause. Specific survival was also analyzed. OS was 
estimated using Kaplan-Meier curves. Prognostic factors for OS were evaluated using the 
log-rank test in univariate analysis. Factors validated in univariate analysis were further 
tested in multivariate analysis. Results are reported as hazard-ratios (HR) with 95% 
confidence intervals. All analyses were conducted using SAS software (version 9.1; SAS 
Institute, Cary, NC). 
Results 
Population  
Out of the 222 patients identified as included in the Mapp-prono study in the ENS@T 
database, causes of exclusion were: diagnosis of metastatic disease before 1998 or after 2010 
in 6 or 38 cases respectively, benign tumor in 1 case, and proximal metastatic lymph nodes 
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The median time between initial diagnosis and T0 was 43 months (range 0-614). The 
metastases were diagnosed within the first year in 79 patients (47%). A delayed diagnosis 
was observed with a time since the initial diagnosis above 5 and 10 years in 47 (28%) and 26 
(15%) of the patients respectively.  
At T0, a slight predominance of male was found (55%) and the mean age of the cohort 
was 48 ± 16 years (range 10-80). The primary tumor was located in the adrenal in 90 patients 
(53%) and at extra-adrenal sites in 79 patients (47%) including abdomen/pelvis or 
thoracic/neck in 63 and 16 patients, respectively. Twenty-two patients (13%) had multiple 
primaries. Ninety-four patients (57%) had tumor-related symptoms at presentation and 96 had 
hormone-related symptoms (58%). Fifty-three patients (32%) presented both tumor and 
hormone-related symptoms at T0 whereas 29 (17%) had no symptoms. Hormonal secretion 
as defined by an excess of Chromogranin A and or metanephrine/normetanephrine 
(MN/NMN)  was reported in 117 out of 145 patients evaluable (81%) and elevated MN/NMN 
were found in 100 patients (72%). The size of the primary was available for 144 patients and 
was above 5 centimeters in 109 of them (76%). In patients with available pathological 
reports, the mitotic count exceeded 3 per high-power field (HPF) in 22 out of 83 patients 
(27%) and Ki67 was measured as follow: between 2 and 10% in 19 (40%) and above 10% in 
18 patients (38%) out of 47 patients .The bone was the most frequent site of metastases 
(64%) and 35 patients (21%) had isolated bone metastases at presentation. The others 
metastatic organs were: distant lymph nodes (40%), lung (29%) and liver (26%). Seventy-
three patients (43%) had metastases in both bone and soft tissues whereas 61 patients (36%) 
had no bone metastases. Fludeoxyglucose-positron emission tomography (FDG-PET) was 
positive for 94 patients out of 98 (96%). Of the four patients with negative FDG-PET, 2 had a 
neurofibromatosis type 1 (NF1) and 2 have an apparently sporadic disease. Characteristics of 
patients according to their primary location are reported in Table 2: patients with malignant 
pheochromocytoma were characterized by less frequent genetic disease, tumor-related 
symptoms or bone metastasis as compared to malignant paraganglioma. 
Genetic features of the cohort 
A mutation of a gene encoding a succinate dehydrogenase subunit was found in  70 patients 
including 63 SDHB mutation carriers (42%), 6 SDHD mutation carriers and 1 SDHC 
mutation carrier. Others 69 patients (46%), defined as apparently sporadic underwent a 
negative genetic screening including at least SDHB. Four patients had a clinical history of 
NF1, 4 patients had a Von Hippel Lindau disease (VHL) and 3 a multiple endocrine neoplasia 
type 2 (MEN2). At the end, patients can be classified into different subgroups depending on 
the cluster according to the unsupervised classical transcriptomic classification described for 
paraganglioma with 75 patients belonging to cluster 1 (50%); 4% to cluster 2 and 46% with 
sporadic MPP (25). Main characteristics of patients according to their genetic status are 
reported in Table 3. Finally, the genetic status was unknown for 18 patients (11%). Patients 
with sporadic tumors were characterized by older age at T0, higher median time to T0, 
adrenal primary and soft tissue metastases only as compared to cluster 1 patients. 
Prognostic factors for survival in the cohort 
The median follow-up from T0 was 64 months (range 0.5-185). Median overall survival was 
6.7 years and 5-year overall survival was 62%. Seventy-eight of the 92 deaths were reported 
as related to the MPP (85%). Because no difference between overall and specific survival 
analyses was found, parameters affecting overall survival only were reported as described in 
Table 4. At univariate analysis (Figure 1), head and neck paraganglioma, younger age, 
absence of or low hormonal secretion (under 5 time upper normal range) and low 
proliferative index (as defined by mitosis ≤ 3/10 HPF and or Ki67 ≤ 2%) were significantly 
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index were excluded from the multivariate analysis because of their small number (Table 4). 
At multivariate analysis hypersecretion (HR 3.02[1.65-5.55]; p:0.0004) was identified as 
independent significant prognostic factors of worst overall survival.  
Discussion 
To the best of our knowledge, this series is the largest cohort of adult patients with MPP. Our 
aim was to progress in the prognostic stratification of this heterogeneous groups of 
neuroendocrine tumors.  Our results do not confirm SDHB mutations as a major prognostic 
parameter in MPP and suggest additional key molecular events involved in MPP tumor 
progression. Primary tumor location and genetics were found highly intricated with MPP 
characterization. 
Our series confirm several critical characteristics of MPP patients that include a 
prolonged disease-free interval justifying lifelong follow-up especially in asymptomatic 
patients. We found SDHB mutation in 42% of cases and well balanced pheochromocytoma 
and paraganglioma origin as expected because of the lower rate of malignancy but higher 
frequency of pheochromocytoma. We also found frequent bone locations isolated in 22% of 
cases urging specific bone site screening. Furthermore, in our cohort, the primary size was 
above 5 cm in 76% of cases.  
The five-year survival was 62% in the range of published series (4–7). Interestingly, the 
vast majority of deaths were classified as MPP-related and, no difference was found in 
between OS and DSS analysis, suggesting that overall survival constitute a valuable primary 
endpoint in this group of tumors. Highlighted prognostic parameters deserve further 
comments. First patients with head and neck paraganglioma by contrast with other 
paraganglioma locations were associated with improved prognosis in univariate analysis but 
also a trend was found in multivariate analysis. Our result suggests that primary location of 
MPP could be considered at the time of prognostic stratification in two separate categories: 
head and neck paraganglioma and pheochromocytoma/abdomen-pelvic paraganglioma. We 
do not confirm the pejorative prognostic role of paraganglioma site as compared to 
pheochromocytoma in MPP and suggest that paraganglioma location may cover different 
entities with various behaviors. Larger series are required to definitely validate this 
hypothesis. Second, as for other well differentiated neuroendocrine tumors, hypersecretion 
but not hormonal or tumor symptoms was found pejorative. These biomarkers may be 
considered as reliable surrogates of both the secretory activity of the tumor but also the tumor 
burden. The efficacy of systemic but also local therapeutic options including surgery in 
reducing these secretions remains to be further explored. In line with that comment, the fact 
that the tumor burden as pointed out by the number or type of metastasized organs did not 
emerge as a prognostic parameter in our study is intriguing  and may suggest insufficient 
tumor characterization in centers, still. Indeed, all patients underwent a thoracic abdominal 
and pelvic imaging but information on TEP imaging is missing in 58% of them. Third, 
genetics was found prognostic as defined by a worse prognosis of sporadic MPP. SDHB 
status was analyzed in 151 out of 169 patients (89%). Half of the patients with MPP harbor a 
mutation belonging to the cluster 1. That SDHB mutation rate is conformed to the other 
published series. But, in line with recent publications in the field, we do not confirm a 
prognostic role of SDHB mutation, which remains questionable. Indeed, SDHB was initially 
considered a risk factor for malignancy and secondly hypothesized as potentially carrying a 
prognostic value. Our results suggest that these two roles could be dissociated and additional 
molecular markers of tumor aggressiveness involved beyond SDHB mutation. However, 
confounding factors of this reasoning should be kept in mind: SDHB patient characteristics 
were associated with other favorable prognostic factors such as: younger age, earlier 
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paraganglioma and absence of hypersecretion. In addition, SDHB patients may respond better 
to systemic therapy and benefit from a better surveillance screening. We also observe a trend 
for a better prognosis for patients with prolonged disease free interval and low Ki67. Both 
parameters constitute markers of tumor growth velocity that may constitute useful additional 
factors at the time of the therapeutic decision. As proposed in one earlier study, we therefore 
propose to evaluate the spontaneous radiological tumor rate of progression, as a surrogate of 
disease free interval, but also proliferative index in future prognostic studies (4). 
Limitations of our study include the absence of functioning imaging in all patients, 
absence of consistent analysis of proliferative index and also metoxytyramine evaluation. In 
addition, the scarcity and retrospective nature of our study constitute well known limitations 
when evaluating rare cancers. 
To conclude, MPP patients with sporadic disease and hypersecretion experienced a worst 
overall survival. Head and neck paraganglioma, may constitute a new favorable prognostic 
category. We recommend that treatments should aim at reducing the “secretory burden”. The 
prognostic relevance of SDHB mutation is challenged. Efforts to implement international 
cohorts of well characterized MPP patients should be done to progress in the prognostic 
stratification. 
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Figure 1: Overall survival of MPP Patients according to (A) Primary location (B) Age at 
T0 (C) Disease free interval (D) Genetic status (E) Hormonal secretion and (F) 
Proliferative index. Cluster 1 genetic status includes patients with a SDHx or MDH2 
mutation and VHL disease; cluster 2 genetic status includes patients with MEN2 and NF1. 
Hypersecretion is defined as high if CgA and/or metanephrines > 5N; Proliferative index is 
defined as high if mitosis count is > 3/10 HPF and/or Ki67 > 2%. 
Table 1: Demographics and baseline characteristics of patients at T0 
Characteristics  N evaluable n 
(%) 
Total n (%) 
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Sex ratio (M/F)   169 (100) 93/76 (55/45) 
Age at T0  169 (100) 48 years ± 16 
Primary tumor site  169 (100)  
adrenal 90 (53) 
extra-adrenal 79 (47) 
Tumor-related symptoms 169 (100) 94 (57) 
Hormones-related symptoms 169 (100) 96 (58) 
Hypersecretion * 145 (86) 117 (81) 
Pathology    
Size > 5 cm 144 (85)               109 (76) 
Mitotic count > 3/10 HPF              83 (49)               22 (27) 
Ki 67   
2-10%  19 (40) 
>10%              47 (28)              18 (38) 
Time between initial diagnosis and malignancy  169 (100)  
M1 within a year 79 (47) 
M1 > 5 year  47 (28) 
Metastatic site 169 (100)  
Bones  108 (64) 
Lymph nodes 67 (40) 
Lung 49 (29) 
Liver 44 (26) 
 98 (58) 94 (96) 
FDG-PET  
Positive  
Genetics  151 (89)  
No mutation 69 (46) 
NF1 clinical screening 4 
MEN2 3 
VHL 4 




Figures represent the number of evaluable patients (%) or means ± SD. 
*Hypersecreting tumor is defined as CgA and/or metanephrines > 2N  
Table 2: Characterization of patients according to the primary 
Characteristics Adrenal N (%) AbdoP PGL N (%) HN PGL N (%) 
N 90 63 16 
Male  66 (73) 35 (56) 6 (37) 
Age at T0 (year) 48,2 48,3 47,2 
M1 < 1 year 39 (43) 33 (52) 7 (44) 
Genetics 
N evaluable 76 59 16 
Sporadic 52 (68) 13 (21) 4 (25) 
SDHB 12 (13) 42 (67) 9 (56) 
SDHC / SDHD / MDH2 0 / 1 / 0 1 / 2 / 1 0 / 3 / 0 
VHL / MEN2 / NF1 4 / 3 / 4 0 0 
Tumor-related syndrome 41/87 (47) 40 (63) 13 (81) 
Hormone-related syndrome 53/87 (61) 39 (62) 4 (25) 
Hypersecretion*  71/80 (89) 42/53 (79) 3/12 (25) 
Metastases 
Bone only 14 (16) 15 (24) 6 (37) 
Soft tissue only 49 (54) 19 (30) 5 (31) 
Figures represent the number of evaluable patients (%), means ± SD, or median [IQR]. 
*Hypersecreting tumor is defined as CgA and/or metanephrines > 2N 
AbdoP PGL: abdomino-pelvic paraganglioma; HN PGL: head and neck paraganglioma.  
Table 3: Characterization of patients according to genetics 
Characteristics  Cluster 1 N (%) Sporadic N (%) p 
Number  75 69  
Males 38 (51) 40 (58) NS 










































































































































































The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2018-01968 
 
 10
Median time to T0 (months)  4.1 [0-613] 26.9 [0-313] 0.021 
M1 within a year 43 (58) 23 (33) 0.004 
Primary tumor site     
adrenal 17 (23) 52 (75) < 0.0001 
HN PGL 12 (16) 4 (6) 0.051 
AbdoP PGL 46 (61) 13 (19) < 0.0001 
multiples 15 (20) 5 (7)  0.027 
Tumor-related symptoms 45 (60) 34 (49) NS 
Hormone-related symptoms 40 (53) 40 (58) NS 
Hypersecretion * 49 (65) 48 (70) NS 
Metastatic site    
Bone only  20 (27) 11 (16) NS 
Soft tissue only  20 (27) 43 (62) < 0.0001 
Figures represent the number of evaluable patients (%), means ± SD, or median [IQR]. 
*Hypersecreting tumor is defined as CgA and/or metanephrines > 2N 
AbdoP PGL: abdomino-pelvic paraganglioma; HN PGL: head and neck paraganglioma.  
Table 4: Univariate and Multivariate Analysis of the association of prognostic factors with 
Overall Survival (OS) 
Parameter Univariate Analysis Multivariate Analysis 
 HR [95% CI] P-value HR [95% CI] P-value 
Sex  0.62   
M 1 
F 1.11 [0.73-1.68] 
Primary     0.023  0.097 
Adrenal 1 1 
Head and Neck 0.15 [0.04-0.62] 0.35 [0.07-1.62] 
Abdomino-pelvic 0.78 [0.51-1.2] 1.44 [0.8-2.59] 
Age at T0 (years)  0.038  0.13 
< 40  1 1 
40-60 1.82 [1.07-3.09] 1.57 [0.84-2.92] 
> 60  2.12 [1.15-3.91] 2.08 [1.04-4.17] 
Disease free interval (years)  0.093  0.28 
< 1 1 1 
1-5 1.02 [0.63-1.65] 0.77 [0.39-1.53] 
> 5 0.58 [0.34-0.98] 0.58 [0.3-1.14] 
Genetics  <0.0001  0.53 
Sporadic and Cluster 2* 1 1 
Cluster 1 0.71 [0.44-1.13] 0.78 [0.38-1.62] 
Metastatic site  0.56   
Bone only 1 
Soft tissue only 0.81 [0.46-1.41] 
Both 1.02 [0.58-1.79] 
Nb of metastatic sites  0.18   
1 1 
2 0.72 [0.44-1.17] 
3 1.30 [0.74-2.3] 
4 1.37 [0.64-2.95] 
Tumor-related syndrome  0.70   
No 1 
Yes 1.20 [0.79-1.82] 
Unknown 1.02 [0.24-4.23] 
Hormone-related syndrome  0.95   
No 1 
Yes 0.94 [0.62-1.44] 
Unknown 0.89 [0.21-3.68] 
Hypersecretion  0.0008  0.0004 
Absent or low  1 1 
High 2.42 [1.45-4.05] 3.02 [1.65-5.55] 
Proliferative index  0.006  0.19 
Low 1 1 
High 2.39 [1.39-4.1] 2.07 [0.94-4.53] 
HR: hazard ratio, Hypersecretion is defined as high if  CgA and/or metanephrines > 5N; Proliferative index is 
defined as high if mitosis count is > 3/10 HPF and/or Ki67 > 2% 
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